DOCSLIB.ORG

Kentucky Controlled Substances by Schedule II-V(*Not All Trade Names Included)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

KY Scheduled Drug List (updated 1/11/2021) Kentucky Controlled Substances by Schedule II-V (*not all trade names included) Note differences in KY schedule and federal schedule: pentazocine (Schedule III in KY, Schedule IV federally) nalbuphine (Schedule IV in KY, not scheduled federally) gabapentin (Scheduled V in KY, not scheduled federally) barbital, methylphenobarbital and phenobarbital (Schedule III in KY, Schedule IV federally) --Be advised--KY does not exempt ANY butalbital product from the Control Substance Act (902 KAR 55:045) DEA CSA Other Names (*not all trade names Substance Narcotic Notes Number Schedule included) 1-Phenylcyclohexylamine 7460 II N Precusor of PCP 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, precusor of PCP 4-Anilino-N-phenethylpiperidine 8333 II N ANPP, Despropionyl fentanyl Alfentanil 9737 II Y Alfenta Alphaprodine 9010 II Y Nisentil Amobarbital 2125 II N Amytal, Tuinal Adzenys ER/XR-ODT, Dyanavel XR, Amphetamine 1100 II N Evekeo, Evekeo ODT Anileridine 9020 II Y Leritine Benzhydrocodone combination products 9193 II Y Apadaz Bezitramide 9800 II Y Burgodin Carfentanil 9743 II Y Wildnil Coca Leaves 9040 II Y Cocaine 9041 II Y Goprelto nasal sol, Numbrino Codeine 9050 II Y Morphine methyl ester, methyl morphine Dexmethylphenidate 1724 II N Focalin, Focalin XR Dextroamphetamine 1100 II N Dexedrine, ProCentra, Zenzedi Dextroamphetamine/amphetamine 1100 II N Adderall, Adderall XR, Mydayis ER Dextropropoxyphene, bulk (non-dosage forms) 9273 II Y Propoxyphene Dihydrocodeine 9120 II Y Didrate, Parzone Dihydroetorphine 9334 II Y DHE Diphenoxylate 9170 II Y Dronabinol in Oral Solution in Drug Product Approved 7365 II N Syndros for Marketing by US Food and Drug Admin. Ecgonine 9180 II Y Cocaine precursor, in Coca leaves Ethylmorphine 9190 II Y Dionin Etorphine HCl 9059 II Y M 99 Innovar, Sublimaze, Fentora, Duragesic, REMS enrollment required for Fentanyl 9801 II Y Actiq, Lazanda, Onsolis, Subsys, Abstral TIRF products. Glutethimide 2550 II N Doriden, Dorimide Hydrocodone (dihydrocodeinone) 9193 II Y Hysingla ER, Vantrela ER, Zohydro ER Lorcet HD/plus, Lortab elix/plus, Norco, Tussionex, Tussicaps, Tussigon, Hycet, Combination products moved from Hydrocodone combination products 9193 II Y Hycodan, Hydromet, Ibudone, Repraxain, Schedule III to Schedule II (dihydrocodeinone) Xodol, Vicodin, Vicodin HP/ES, effective October 6, 2014 Vicoprofen, Vituz Hydromorphone (dihydromorphinone) 9150 II Y Dilaudid, Exalgo Isomethadone 9226 II Y Isoamidone LAAM, long acting methadone, Levo-alphacetylmethadol 9648 II Y levomethadyl acetate Levomethorphan 9210 II Y Levorphanol 9220 II Y Levo-Dromoran Lisdexamfetamine 1205 II N Vyvanse Meperidine 9230 II Y Demerol, Mepergan Meperidine intermediate-A 9232 II Y Meperidine precursor Meperidine intermediate-B 9233 II Y Meperidine precursor Meperidine intermediate-C 9234 II Y Meperidine precursor Metazocine 9240 II Y Methadone 9250 II Y Dolophine, Methadose Methadone intermediate 9254 II Y Methadone precursor Methamphetamine 1105 II N Desoxyn, D-desoxyephedrine Page 1 of 6 KY Scheduled Drug List (updated 1/11/2021) DEA CSA Other Names (*not all trade names Substance Narcotic Notes Number Schedule included) Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Metadate Methylphenidate 1724 II N CD/ER , Methylin, Methylin ER, Quillichew, Quillivant XR, Ritalin, Ritalin LA, Jornay PM Metopon 9260 II Y Moramide-intermediate 9802 II Y MS Contin, Roxanol, Duramorph, RMS, Morphine 9300 II Y MSIR, Avinza, Kadian, Oramorph, Arymo ER, Inumorph, Mitigo, MorphaBond ER Morphine-Naltrexone 9300 II Y Embeda Nabilone 7379 II N Cesamet Norfentanyl 8366 II Y Noroxymorphone 9668 II Y Oliceridine 9245 II Y Olinvyk Opium extracts 9610 II Y Opium fluid extract 9620 II Y Opium poppy 9650 II Y Papaver somniferum Opium tincture 9630 II Y Laudanum Opium, granulated 9640 II Y Opium, powdered 9639 II Y Opium, raw 9600 II Y Opium & Belladonna alkaloids 9639 II Y B&O Supp Oripavine 9330 II Y Roxibond, Roxicodone, Oxaydo, Oxycodone 9143 II Y Oxycontin, Xtampza ER Endocet, Endodan, Percocet, Percodan, Oxycodone combination products 9143 II Y Primlev, Targiniq ER, Troxyca ER, Xartemis XR, Prolate Oxymorphone 9652 II Y Numorphan, Opana ER Pentobarbital 2270 II N Nembutal Phenazocine 9715 II Y Narphen, Prinadol Phencyclidine 7471 II N PCP, Sernylan Phenmetrazine and salts 1631 II N Preludin P2P, phenyl-2-propanone, benzyl methyl Phenylacetone 8501 II N ketone Piminodine 9730 II Y Poppy Straw 9650 II Y Opium poppy capsules, poppy heads Poppy Straw Concentrate 9670 II Y Concentrate of Poppy Straw, CPS Racemethorphan 9732 II Y Racemorphan 9733 II Y Dromoran Remifentanil 9739 II Y Ultiva Secobarbital 2315 II N Seconal, Tuinal Sufentanil 9740 II Y Dsuvia REMS enrollment required Tapentadol 9780 II N Nucynta, Nucynta ER Thebaine 9333 II Y Precursor of many narcotics Thiafentanil 9729 II Y Thianil Amobarbital & noncontrolled active ingredient 2126 III N Amobarbital/ephedrine capsules Amobarbital suppository dosage form 2126 III N Anabloic steroids are listed specifically in Title 20 CFR Anabolic steroids 4000 III N "Body Building" drugs §1300.01 (Defintions relating to controlled substances). Androstanedione (5alpha-androstan-3,17-dione) 4000 III N Aprobarbital 2100 III N Alurate Schedule III in KY (902 KAR Barbital 2145 III N Veronal, Plexonal, barbitone 55:015). Schedule IV federally. Barbituric acid derivative 2100 III N Barbiturates not specifically listed Benzphetamine 1228 III N Didrex, Inapetyl, Rigamix Bolasterone (7alpha,17alpha-dimethyl- 4000 III N 17betahydroxyandrost-4-en-3-one) Equipoise, Parenabol, Vebonol, Boldenone 4000 III N dehydrotestosterone Boldione 4000 III N Page 2 of 6 KY Scheduled Drug List (updated 1/11/2021) DEA CSA Other Names (*not all trade names Substance Narcotic Notes Number Schedule included) Belbuca, Buprenex, Subutex, Butrans, Suboxone, Zubsolv, Bunavail, Buprenorphine 9064 III Y Probuphine (REMS), Sublocade (REMS), Cassipa Butabarbital (secbutabarbital) 2100 III N Butisol, Butibel Effctive September 17, 2014, all Capacet, Fiorinal, Fiorocet, Esgic, prescription products containing Butalbital and noncontrolled active ingredient 2100 III N Phrenlin, Bupap, Vanatol LQ, Zebutal, butalbital are Schedule III Vtol Liq, Allzital medications in KY (902 KAR 55: 045 -NO exemptions). Butobarbital (butethal) 2100 III N Soneryl (UK) Calusterone (7beta,17alpha-dimethyl- 4000 III N Methosarb 17betahydroxyandrost-4-en-3-one) Mechloral, Mecoral, Medodorm, Chlorhexadol 2510 III N Chloralodol Chlorphentermine 1645 III N Pre-Sate, Lucofen, Apsedon, Desopimon Clortermine 1647 III N Voranil Alfa-Trofodermin, Clostene, 4- Clostebol 4000 III N chlorotestosterone Codeine & isoquinoline alkaloid not more than 90 9803 III Y Codeine with papaverine or noscapine mg/dosage unit Ascomp w/cod, Tylenol #3, Tylenol #4, Codeine combination product not more than 90 Fioricet w/ codeine, Fiorinal w/codeine, 9804 III Y mg/dosage unit Allfen CD, Tuzastra XR, Tuxarin ER, Soma compound w/codeine Dehydrochlormethyltestosterone 4000 III N Oral-Turinabol Desoxymethyltestosterone 4000 III N Dihydrocodeine combination product 90 mg/dosage 9807 III Y Dvorah, Synalgos-DC, Compal, Trezix unit Anabolex, Andractim, Pesomax, Dihydrotestosterone 4000 III N Stanolone Dronabinol in sesame oil in soft gelatin capsule 7369 III N Marinol Drostanolone 4000 III N Drolban, Masterid, Permastril Embutramide 2020 III N Tributane Esketamine III N Spravato REMS enrollment required Maxibolin, Orabolin, Durabolin-O, Ethylestrenol 4000 III N Duraboral Ethylmorphine combination product not more than 15 9808 III Y mg/du Androxy, Anadroid-F, Halotestin, Ora- Fluoxymesterone 4000 III N Testryl Formebolone 4000 III N Esiclene, Hubernol Furazabol 4000 III N Frazolon, Miotolone, Qu Zhi Shu Gamma Hydroxybutyric Acid preparations (GHB) 2012 III N sodium oxybate,Xyrem, Xywav REMS enrollment required Ketamine 7285 III N Ketaset, Ketalar, Special K, Ketamine combination 7285 III N MKO Melt Dose Pack, MKH Dose Pack Lysergic acid 7300 III N LSD precursor Lysergic acid amide 7310 III N LSD precursor 4000 III N Assimil, Ermalone, Methybol, Tantarone Mestanolone Mesterolone 4000 III N Andrviron, Proviron, Testiwop Methandienone 4000 III N Dianabol, Metabolina, Nerobol, Perbolin Methandriol 4000 III N Sinesex, Stenediol, Troformone Methasterone 4000 III N Primobolan, Primobolan Depot, Methenolone 4000 III N Primobolan S Methyldienolone 4000 III N Methyltestosterone 4000 III N Android, Oreton, Testred, Virilon Some products with no significant potential for abuse specifically Methyltestosterone combinations with estrogens 4000 III N EEMT, EEMT HS, Covaryx, Covaryx HS exempted (see 902 KAR 55:090/CFR 1308.34). Link to current list. Page 3 of 6 KY Scheduled Drug List (updated 1/11/2021) DEA CSA Other Names (*not all trade names Substance Narcotic Notes Number Schedule included) Methyltrienolone 4000 III N Metribolone Schedule III in KY (902 KAR Methylphenobarbital (mephobarbital) 2250 III N Mebaral, mephobarbital 55:015). Schedule IV federally. Methyprylon 2575 III N Noludar Mibolerone 4000 III N Cheque, Metenon Morphine combination product not more than 50 9810 III Y mg/(100 ml or 100gm) Nalorphine 9400 III Y Nalline Nandrolone 4000 III N Deca-Durabolin, Durabolin, Durabolin-50 Norbolethone 4000 III N Genabol Norclostebol 4000 III N Anabol-4-19, Lentabol Norethandrolone 4000 III N Nilevar, Pronabol, Solevar Normethandrolone 4000 III N Lutenin, Matronal, Orgasteron Opium combination product not more than 25 mg/du 9809 III Y Paregoric, other combination products
Recommended publications
  • An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. P

    An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. P

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 17 November 2020 doi:10.20944/preprints202011.0443.v1 An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. Pande1, Brian J. Piper1,2* 1Department of Medical Education, Geisinger Commonwealth School of Medicine 2Center for Pharmacy Innovation and Outcomes * Brian J. Piper, Ph.D.525 Pine Street, Geisinger Commonwealth School of Medicine Scranton, PA 18411, USA Abstract: Buprenorphine, an analogue of thebaine, is a Schedule III opioid in the United States used for opioid-use disorder and as an analgesic. Research has shown drugs like buprenorphine have a complicated pharmacology with characteristics that challenge traditional definitions of terms like agonist, antagonist, and efficacy. Buprenorphine has a high affinity for the mu (MOR), delta (DOR), kappa (KOR), and intermediate for the nociceptin opioid receptors (NOR). Buprenorphine is generally described as a partial MOR agonist with limited activity and decreased response at the mu- receptor relative to full agonists. In opioid naïve patients, the drug’s analgesic efficacy is equivalent to a full MOR agonist, despite decreased receptor occupancy and the “ceiling effect” produced from larger doses. Some argue buprenorphine’s effects depend on the endpoint measured, as it functions as a partial agonist for respiratory depression, but a full-agonist for pain. Buprenorphine’s active metabolite, norbuprenorphine, attenuates buprenorphine's analgesic effects due to NOR binding and respiratory depressant effects. The method of administration impacts efficacy and tolerance when administered for analgesia. There have been eleven-thousand reports involving buprenorphine and minors (age < 19) to US poison control centers, the preponderance (89.2%) with children.
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity

    Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity

    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
  • Screening/Spot Test of Narcotics

    Screening/Spot Test of Narcotics

    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
  • These Highlights Do Not Include All the Information Needed to Use BENZHYDROCODONE and ACETAMINOPHEN TABLETS Safely and Effectively

    These Highlights Do Not Include All the Information Needed to Use BENZHYDROCODONE and ACETAMINOPHEN TABLETS Safely and Effectively

    BENZHYDROCODONE AND ACETAMINOPHEN- benzhydrocodone and acetaminophen tablet KVK-Tech, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BENZHYDROCODONE AND ACETAMINOPHEN TABLETS safely and effectively. See full prescribing information for BENZHYDROCODONE AND ACETAMINOPHEN TABLETS. BENZHYDROCODONE AND ACETAMINOPHEN tablets, for oral use, CII Initial U.S. Approval: 1982 WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE- THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS See full prescribing information for complete boxed warning. Benzhydrocodone and Acetaminophen tablets exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions. (5.1) To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. (5.2) Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. (5.3) Accidental ingestion of Benzhydrocodone and Acetaminophen tablets, especially by children, can result in a fatal overdose of hydrocodone. (5.3) Prolonged use of Benzhydrocodone and Acetaminophen tablets during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
  • Chronic Use of Opioid Medications Before and After Bariatric Surgery

    Chronic Use of Opioid Medications Before and After Bariatric Surgery

    Supplementary Online Content Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. doi:10.1001/jama.2013.278344 eFigure. Opioid Dispensings in 60 Days Before and 60 Days After Bariatric Surgery eTable 1. Opioid Classification and Morphine Equivalents Conversion Factors for Opioids Administered by Tablet, Capsule, Liquid, Transdermal Patch, and Transmucosal Formulations eTable 2. ICD-9 Codes for Comorbid Diagnosis of Substance Abuse, Anxiety, Posttraumatic Stress Disorder, and/or Depression eTable 3. ICD-9 Codes for Inclusion and Exclusion of Chronic Pain Diagnoses eTable 4. Therapeutic Classes, Generic Names, and Selected Brand Names of Covariate Medications eTable 5. Types of Opioids Dispensed During the Year Before and the Year After Bariatric Surgery Among Presurgery Chronic Opioid Users eTable 6. Types of Opioids Used Before and After Bariatric Surgery Among 933 Individuals With Chronic Opioid Use Before Bariatric Surgery eTable 7. Unadjusted Characteristics of Chronic Opioid Users According to Whether or Not Both Presurgery and Postsurgery Body Mass Indexes (BMIs) Data Were Available eTable 8. Presurgery and Postsurgery Use of Opioids and Selected Other Analgesic and Adjunctive Pain Medication Classes Among Presurgery Chronic Opioid Users With Presurgery Chronic Pain Diagnoses This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From:
  • Summary Analgesics Dec2019

    Summary Analgesics Dec2019

    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
  • Use of Analgesics in Exotic Felids Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University Of

    Use of Analgesics in Exotic Felids Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University Of

    Use of Analgesics in Exotic Felids Formatted: Centered Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University of Tennessee, and Consulting Veterinarian, Knoxville Zoological Gardens, Knoxville, Tennessee. Corresponding address: Ed Ramsay Dept. of Sm Animal Clin Sci C247, Veterinary Teaching Hospital University of Tennessee Knoxville, TN 37996-4544 Phone: 865-755-8219 FAX: 865-974-5554 Email: [email protected] 2 Treatment of pain in domestic and non-domestic cats has been a challenge for the clinician. Many cat species are stoic and show few or very subtle external signs of pain. Additionally, the adverse effects of nonsteroidal antiinflammatory drugs (NSAIDs) in domestic cats are well documented and have discouraged many practitioners from trying novel NSAID’s in exotic felids. As in other animals, each cat’s response to pain and analgesics will vary, necessitating an individualized treatment plan. As a rule, always treat painful felids to effect, and not by rote reliance on published dosages. It is frequently necessary to try different agents and combinations to find which produces the optimal analgesic effect in exotic felids. In order to minimize adverse effects, it is desirable to work toward treatment with the lowest effective dose when treating chronic pain. Non-steroidal Antiinflammatory Drugs NSAIDs are antiinflammatory drugs which act both centrally and peripherally. The primary effects are believed to be caused by their ability to inhibit cyclooxygenase (COX) enzymes in the arachidonic acid metabolism cascade. The COX-1 isoform is regarded as constitutive (continuously expressed) and is responsible for many homeostatic processes, such as maintenance of gastric mucosal integrity, platelet function, and renal autoregulation.
  • BUTALBITAL ANALGESICS Allzital (Butalbital-Acetaminophen

    BUTALBITAL ANALGESICS Allzital (Butalbital-Acetaminophen

    BUTALBITAL ANALGESICS Allzital (butalbital-acetaminophen), butalbital-aspirin-caffeine, butalbital-aspirin-caffeine- codeine, butalbital-acetaminophen, butalbital-acetaminophen-caffeine, butalbital- acetaminophen-caffeine-codeine, Vanatol LQ (butalbital-acetaminophen-caffeine liquid oral solution) RATIONALE FOR INCLUSION IN PA PROGRAM Background Butalbital containing products are non-opioid analgesics that contain a combination of different drug products indicated for the relief of the symptom complex of tension (or muscle contraction) headache pain. Butalbital is a short to intermediate-acting barbiturate that works in concert with acetaminophen, an antipyretic non-salicylate agent, aspirin, a pain-relieving NSAID, and caffeine, a stimulant that works in the CNS, to decrease pain via a mechanism that isn’t well understood. Butalbital is a habit-forming drug that potentiates the effects of other commonly abuse drugs or substances like alcohol. Caffeine might help increase vasodilation and smooth muscle relaxation, while butalbital is thought to help balance the CNS stimulation caused by caffeine and produces depressant effects (1). Regulatory Status FDA approved indication: Butalbital containing products are used in the relief of the symptom complex of tension or muscle contraction headaches (2-8). Frequent use of acute medications is generally thought to cause medication-overuse headache. To decrease the risk of medication-overuse headache (“rebound headache” or “drug-induced headache”) many experts limit acute therapy to two headache days per week on a regular basis. Based on concerns of overuse, medication-overuse headache, and withdrawal, the use of butalbital-containing analgesics should be limited and carefully monitored. The Allzital limit is set to the maximum of 12 doses per day for acute treatment of 8 headaches per month as this product contains less butalbital than other products.
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register/Vol. 85, No. 178/Monday, September 14, 2020

    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
  • Misperceptions About Contraceptives Persist

    Misperceptions About Contraceptives Persist

    30 Women’s Health FAMILY P RACTICE N EWS • September 1, 2008 Misperceptions About Contraceptives Persist BY DOUG BRUNK trauterine device use; 50% thought IUD (SOGC). There may be inadequate in- Oral contraceptives are also safe in women San Diego Bureau failure was a major risk; and fewer than struction with regard to contraception in older than age 35 if they are healthy non- one-third would recommend an IUD as an physician-training programs, she said. smokers, and in women with systemic lu- C ALGARY, ALTA. — Physicians may option for nulliparous women, for post- “Not everybody does IUD insertions, sub- pus erythematosus provided they have no have a surprising number of misconcep- coital contraception, for women with fi- dermal progestin implant, or vasectomy.” antiphospholipid antibodies, vascular dis- tions about birth control, according to re- broids, or for women who had pelvic in- Other barriers to effective contraceptive ease, or nephritis. cent responses to a survey by 96 family flammatory disease within the last year use include exaggerated concerns about Another common exaggerated concern physicians in Kingston, Ont. (Can. Fam. Physician 2008;54:560-6). potential side effects. For example, women is that the use of oral and transdermal Contrary to evidence in the medical lit- “Only 41% of these physicians inserted with diabetes may use oral contraceptives patch contraceptives cause weight gain. erature, more than 60% of respondents IUDs,” Dr. Amanda Black said at the an- if they have no end-organ damage, said Dr. However, a recent Cochrane systematic re- thought pelvic inflammatory disease and nual meeting of the Society of Obstetri- Black of the division of general obstetrics view of randomized, controlled data con- ectopic pregnancy were major risks of in- cians and Gynaecologists of Canada and gynecology at the Ottawa Hospital.
  • Smumedical Journal

    Smumedical Journal

    SMU Medical Journal ISSN : 2349 – 1604 (Volume – 4, No. 1, January 2017) Review Article Indexed in SIS (USA), ASI (Germany), I2OR & i-Scholar (India), SJIF (Morocco) and Cosmos Foundation (Germany) databases. Impact Factor: 3.835 (SJIF) Analytical Aspects with Brief Overview of Depressants Sandeep Kumar1 Nand Gopal Giri2 Ashok Kumar Jaiswal3* Anil Kumar Jaiswal4 1M.Sc. (Forensic Science), LNJN NICFS, New Delhi 110085, 2Assistant Professor, Department of Chemistry, Shivaji College (University of Delhi) Raja Garden, New Delhi 110 027, 3Dept. of Forensic Medicine and toxicology, All India institute of Medical Sciences, New Delhi 110 029.4Assistant Professor, Department of Mathematics, St. Andrew’s PG College, Gorakhpur, UP. *Corresponding author Manuscript received : 30.10.2016 Manuscript accepted: 21.11.2016 Abstract Depressants are drugs that slow down the functions of the central nervous system (CNS). These drugs are used to reduce anxiety and insomnia without drowsiness. The depressants cause relaxed feeling if used in small quantity but cause unconsciousness, vomiting and even death if taken in high quantity. It affects concentration and coordination of a person by slowing down his/ her ability to respond in unexpected situations. These drugs are also attributed for their physiological and psychological effects, eventually in large dose it become lethal. The different 142 SMU Medical Journal, Volume – 4, No. – 1, January, 2017 physical and chemical features of some very often used depressants are discussed in this manuscript. Keyword: Depressant, TLC, UV spectroscopy, HPLC, GLC etc. Introduction The classical depressants are hypnotics (which induce sleep), most antianxiety medicine (diazepam or valium), muscle spasm prevent seizure, but these drugs rapidly develop dependence and tolerance which finally leads to coma and death, so use of these drugs is highly unsafe.